Keywords: Cortex, Biovail, Apakine, Sickle cell disease, Respiratory depression
Cortex sells selected Ampakine compounds and rights to respiratory depression indication to Biovail for up to $25 million
Article | 29 March 2010
California, USA-based Cortex Pharmaceuticals says it has entered into an agreement with Canada’s Biovail Laboratories for certain Ampakine compounds ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
